Scott Rocklage, PhD is the managing partner at 5am Ventures, a life sciences venture capital company that he joined in 2003. 5am Ventures is a technologically forward-thinking company that invests in cutting edge companies who are searching for unexplored methods to diagnose, treat, research and cure an array of medical conditions. With over three decades in healthcare management Dr. Scott Rocklage is well prepared to lead 5am Ventures into the future.
Dr. Scott Rocklage received his B.S. in chemistry from the University of Berkeley and continued to the Massachusetts Institute of Technology where he completed his PhD in chemistry. While a student at M.I.T. he had the good fortune of working with Richard Schrock who was a 2005 Nobel Prize winner for his work in Chemistry. After he graduated Dr. Scott Rocklage led a team in researching homogeneous catalysis. He developed an affinity for the business management side of life sciences and pursued health sciences management with a passion. He became the CEO of Nycomed Salutor and then CEO of Cubist Pharmaceuticals prior to his partnership with 5am Ventures. Read more about him.
Dr. Scott Rocklage has been responsible for the FDA approval of three drugs: Omniscan, Teslascan and Cubicin. His passion for leadership, science and business shine through in his role at 5am Ventures. He is dedicated to sharing his knowledge with others and is currently the Board Chairman at Rennovia, Kinestral and Cidara. He also is a on the Board Pulmatrix and Epirus. His considerable knowledge and education have helped him develop thirty United States patents. He is a prolific writer of over one hundred scientific papers.